Ascendis Pharma’s Outlook by Berenberg Bank
<p>Analysts at Berenberg Bank provided their outlook on <a href='https://financialmodelingprep.com/financial-summary/ASND'>Ascendis Pharma A/S (NASDAQ:ASND)</a>, stating they see long-term potential as the company transitions from a clinical to a commercial stage company. </p>
<p>According to the analysts, near-term upside drivers for SKYTROFA include (1) ongoing conversions of daily injection patients, (2) international sales, and (3) potential upside from label expansions. </p>
<p>As uncertainties remain about future competitive dynamics and pricing pressures, the analysts have lowered their peak revenue estimate, which results in a 10% reduction in their price target to $192 from $213. </p>
<p>The analysts await TransCon PTH (blockbuster potential) Phase III results this month and believe the results, if favorable, would trigger a regulatory filing in Q3 and eventually launch in mid-2023. The analysts believe that investors are meaningfully underestimating the company’s drug delivery technology. The analysts maintained their buy rating on the company.</p>

NASDAQ:ASND